<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2380">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03371420</url>
  </required_header>
  <id_info>
    <org_study_id>PU-AD-00-001</org_study_id>
    <nct_id>NCT03371420</nct_id>
    <nct_alias>NCT02751554</nct_alias>
  </id_info>
  <brief_title>PET Imaging of Subjects Using 124I-PU-AD</brief_title>
  <official_title>PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent&#xD;
      124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or&#xD;
      myeloma) and/or Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first in-human trial of the positron-emitting agent 124I-PU-AD is an open-label pilot&#xD;
      (microdose) study. Up to 10 evaluable subjects who have active disease will be enrolled to&#xD;
      evaluate the PK, metabolism, biodistribution, and radiation dosimetry of 124I-PU-AD.&#xD;
&#xD;
      Following a 28-day screening period, eligible subjects will return to the clinic on Day 1. A&#xD;
      single dose of 124I-PU-AD will be administered by intravenous (IV) injection to subjects.&#xD;
&#xD;
      After 124I-PU-AD tracer injection, PET scans will be performed at 4 time points. At each&#xD;
      time-point, an axial body image is acquired on a state-of-the-art PET-CT scanner. A low-dose&#xD;
      CT will be obtained immediately-prior to PET imaging, at each time-point. Serial blood&#xD;
      samples will also be obtained at multiple time points.&#xD;
&#xD;
      Subjects will be evaluated to ensure that there are no clinically significant ongoing AEs&#xD;
      prior to discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Safety of 124I-PU-AD in subjects as assessed by evaluation of the incidence, nature, and severity of adverse events and serious adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Lymphoma</condition>
  <condition>Solid Malignancy</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>124I-PU-AD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 124I-PU-AD will be administered by intravenous (IV) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PU-AD</intervention_name>
    <arm_group_label>124I-PU-AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET Scan</intervention_name>
    <arm_group_label>124I-PU-AD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draws</intervention_name>
    <arm_group_label>124I-PU-AD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with a diagnosis of cancer and/or Alzheimer's Disease, meeting trial&#xD;
             eligibility criteria as specified below for either disease:&#xD;
&#xD;
             Cancer:&#xD;
&#xD;
               1. Subjects with eligible histologic types of cancer. Eligible histologic types of&#xD;
                  cancer include solid malignancy, myeloma, and lymphoma.&#xD;
&#xD;
               2. Cancer histology confirmed by pathology.&#xD;
&#xD;
               3. Cancerous disease is radiologically-measurable or evaluable as defined by&#xD;
                  published tumor response criteria (including but not limited to RECIST 1.1).&#xD;
&#xD;
             Alzheimer's:&#xD;
&#xD;
               1. Established diagnosis of mild-moderate Alzheimer's disease based upon&#xD;
                  neurological and neuropsychological evaluation following the National Institute&#xD;
                  on Aging - Alzheimer's disease Association criteria that recently revisited the&#xD;
                  NINCDS-ADRDA criteria.&#xD;
&#xD;
               2. Documentation of diagnosis of mild-moderate Alzheimer's disease, as above, by&#xD;
                  board-certified neurologist.&#xD;
&#xD;
          2. Subjects who have both cancer and Alzheimer's Disease, subjects are considered&#xD;
             eligible if they meet all eligibility requirements for either Alzheimer's Disease or&#xD;
             cancer patients, as specified above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has unacceptable pre-study organ function during screening defined as:&#xD;
&#xD;
               1. Bilirubin &gt; 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               2. AST/ALT &gt;2.5 x ULN&#xD;
&#xD;
               3. Albumin &lt; 2 g/dl&#xD;
&#xD;
               4. GGT &gt; 2.5 x ULN (IF Alkaline phosphatase &gt; 2.5 x ULN)&#xD;
&#xD;
               5. Creatinine &gt;1.5 x ULN or creatinine clearance &lt; 60 mL/min.&#xD;
&#xD;
          2. Subject has history of acute major illness (i.e., unstable cardiovascular condition.)&#xD;
&#xD;
          3. Subject has concurrent participation in any interventional studies within 30 days of&#xD;
             first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Morgan, MS, JD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 29, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

